69 Best Pharma Startups to Watch in 2024
How do we build this list? TLDR: Using math and experts.
Last update to the database: May 26, 2024. See changelog.
Join 23,000+ founders, operators and investors.
Seedtable Score Learn how we calculate it here
Sign up to Seedtable Intel to access the entire database
company | score | funding | investors | employees | industries | biz model | city | contact |
---|---|---|---|---|---|---|---|---|
Antibody-Drug Conjugate specialist creating treatments for tough-to-treat cancers. |
$120M · Series B | TCG Crossover, Atlas Ventures, Brandon Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@pheontx.com | |
Biomedical research discovery tool. |
$60M · Series B | ICONIQ Growth, Index Ventures, Pentech Ventures | 51 to 100 | Health Tech, AI, Biotech, Pharma | B2B, SaaS | London, UK | •••••••••••@causaly.com | |
Portfolio of pharmaceutical research and discovery. |
$33M · Series C | Patient Square Capital, Rock Springs Capital, M&G Investments | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@apollotherapeutics.com | ||
Developer of therapies for inflammatory and fibrotic diseases. |
$81M · Series A | Sarsia, p53, Forbion Capital Partners | 11 to 50 | Biotech, Pharma | Oslo, Norway | •••••••••••@callunapharma.com | ||
Biotechnology firm developing antiviral treatments for patients. |
$44M · Series C | Novo A/S, Andera Partners | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@reviral.co.uk | |
Solution for protecting digestive anastomosis, designed to reduce complications. |
$47M | Sofinnova Partners | 1 to 10 | Health Tech, Hardware, Pharma, Manufacturing | B2B | Paris, France | •••••••••••@safeheal.com | |
Patent-protected anti-inflammatory painkiller. |
$6M · Series A | ITV AdVentures | 1 to 10 | Biotech, Pharma | B2C | London, UK | •••••••••••@flarin.co.uk | |
Early detection of Alzheimer's disease (AD) technology. |
$5M · Series A | WA4STEAM, EIC Accelerator, Ship2B | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Barcelona, Spain | •••••••••••@admit-therapeutics.com | |
Diagnosis and treatment of hard-to-treat cancers. |
$24M · Series A | Earlybird Venture Capital, Andera Partners, HealthCap | 11 to 50 | Health Tech, Biotech, Pharma | B2B | Berlin, Germany | •••••••••••@ariceum-therapeutics.com | |
Producer of gut health binding proteins. |
$32M · Series A | Bill & Melinda Gates Foundation, Novo A/S | 1 to 10 | Biotech, Pharma | B2B | Copenhagen, Denmark | •••••••••••@bactolife.com | |
Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases. |
$3M · Series F | The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Omnes Capital, Nestlé Health Science | 51 to 100 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Paris, France | •••••••••••@enterome.com | |
Biotech firm developing treatments for auto-immune diseases. |
$6M · Series A | Fountain Healthcare Partners | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Paris, France | •••••••••••@ermium.com | |
Treatments for genetic bleeding disorders. |
$135M · Series B | Novo A/S, HealthCap | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Copenhagen, Denmark | •••••••••••@hemab.com | |
Supplier of medical cannabis care and medicine. |
$6M · Series A | Leafy Tunnel | 51 to 100 | Health Tech, Agritech, Pharma, Manufacturing, Cannabis | B2B | London, UK | •••••••••••@LYPHEGROUP.com | |
Platform offering diagnostic tools and testing to aid patients in making health-related decisions. |
$6M · Seed | Felix Capital, Cherry Ventures, FJ Labs | 11 to 50 | Health Tech, Fashion, Pharma, Mobile, Ecommerce | B2C | London, UK | •••••••••••@manual.co | |
Drug discovery platform focused on developing small molecule inhibitors. |
$6M · Seed | Sofinnova Partners | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@myricxpharma.com | |
Cancer treatment predictor software. |
$14M · Series A | Hoxton Ventures, Octopus Ventures, Fly Ventures | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@pearbio.com | |
Platform that accelerates drug discovery using advanced computational techniques. |
$17M · Seed | Quantonation, XAnge | 11 to 50 | Health Tech, Biotech, Pharma, Manufacturing | B2B | Paris, France | •••••••••••@qubit-pharmaceuticals.com | |
We enable healthcare companies to digitize patient interactions and translate data into actionable insights. |
$2M · Seed | Thieme, MassMutual Ventures, MMC Ventures | 11 to 50 | Health Tech, AI, Insuretech, Pharma, Business Intelligence | B2B, SaaS | Vienna, Austria | •••••••••••@xund.ai | |
AI drug discovery platform. |
$16M · Series A | M Ventures | 11 to 50 | Pharma | Paris, France | •••••••••••@iktos.ai | ||
Novel antiobiotic researcher to fight antimicrobial resistance. |
$13M · Series C | AMR Action Fund, GSK | 1 to 10 | Biotech, Pharma | B2B | Basel, Switzerland | •••••••••••@bioversys.com | |
Platform that uses AI to improve diagnostics in pathology, aiding drug development and clinical research. |
$5M · Seed | High-Tech Gründerfonds, Ascension Ventures, Wellington Partners | 11 to 50 | Health Tech, AI, Pharma, Data and Analytics, Business Intelligence | B2B, SaaS | Berlin, Germany | •••••••••••@aignostics.com | |
Gene therapy research to tackle genetic diseases. |
$59M · Series A | Gimv | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Zürich, Switzerland | •••••••••••@anjarium.com | |
Cloud-based clinical data platform. |
$6M · Seed | Eight Roads Ventures, Inkef Capital | 101 to 250 | Health Tech, Biotech, Pharma | B2B, SaaS | Amsterdam, Netherlands | •••••••••••@castoredc.com | |
App that streamlines access to your local pharmacy, helping you skip the queue and manage prescriptions from anywhere. |
$1M · Seed | NPA, MedAdvisor | 1 to 10 | Pharma, Mobile, Ecommerce | B2C, Marketplace | London, UK | •••••••••••@charac.co.uk | |
Platform focused on designing and developing new active cancer immunotherapies. |
$5M · Seed | Positron Ventures | Health Tech, Biotech, Pharma | B2B | Amsterdam, Netherlands | •••••••••••@cimcure.com | ||
Biotechnology platform developing advanced recombinant protein production technologies. |
$3M · Seed | Entrepreneur First, Thia Ventures, XAnge | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing | B2B | Paris, France | •••••••••••@corebiogenesis.com | |
Immuno-oncology company treats cancer with antibodies. |
$2M · Series A | AlbionVC, Novartis Venture Fund, Epidarex Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing, Genetics | B2B | London, UK | •••••••••••@epsilogen.com | |
Developer of therapies for treating chronic inflammatory conditions. |
$6M · Seed | Industrifonden, Hadean Ventures | 1 to 10 | Health Tech, Pharma | B2B | Stockholm, Sweden | •••••••••••@gesynta.se | |
Pioneer in precision medicine for psychiatry based in Munich. |
$10M | ALSTIN Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing | B2B | Munich, Germany | •••••••••••@hmnc-brainhealth.com | |
Data capture for clinical trials. |
$2M · Seed | Bpifrance | 11 to 50 | Health Tech, Pharma, Data and Analytics | B2B, SaaS | Paris, France | •••••••••••@kayentis.com | |
We are a translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered proteins. |
$2M | Hoxton Ventures, Bessemer Venture Partners | 11 to 50 | Health Tech, Biotech, Pharma, Manufacturing | B2B | London, UK | •••••••••••@peptone.io | |
Manufacturer of radio-immunotherapeutic drugs for cancer patients. |
$40M · Series A | Novo A/S, Forbion Capital Partners, BioMedPartners | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing | B2B | Brussels, Belgium | •••••••••••@precirix.com | |
Manufacturer of oral drugs that specifically inhibit the enzyme cytidine triphosphate synthase 1 (CTPS1). |
$2M · Seed | Bpifrance, Idinvest Partners, AGORANOV | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Paris, France | •••••••••••@step-ph.com | |
Immunotherapy for the treatment of cancer. |
$1M · Seed | Cancer Research Horizons, UK Innovation & Science Seed Fund | 11 to 50 | Biotech, Pharma | B2C | London, UK | •••••••••••@nk-io.com | |
Biotech R&D specializing in miniprotein-based pharmaceuticals and cellular & gene therapy (CGT) products |
$5M · Series A | Széchenyi Capital Fund Management | 11 to 50 | Biotech, Pharma | Budapest, Hungary | •••••••••••@vrgtherapeutics.com | ||
Short-duration psychedelic medicines developer for neuropsychiatric conditions. |
$40M · Series B | Leafy Tunnel, ATAI Life Sciences | 1 to 10 | Biotech, Pharma | B2C | Oxford, UK | •••••••••••@beckleypsytech.com | |
Early cancer detection diagnostics platform. |
$3M | Inveready | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Madrid, Spain | •••••••••••@amadix.com | |
Solution against constipation using natural preparations. |
$3M · Seed | Calm/Storm Ventures | 1 to 10 | Health Tech, Foodtech, Pharma, Manufacturing | B2B | Berlin, Germany | •••••••••••@apriwell.de | |
Therapeutics treatment for strokes and brain injury. |
$2M · Series A | Caixa Capital Risc, Inveready | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Madrid, Spain | •••••••••••@aptatargets.com | |
Biotech company specializing in synthetic biology and metabolic engineering. |
$11M · Series B | Sofinnova Partners | 11 to 50 | Health Tech, Biotech, Pharma, Manufacturing | B2B | Copenhagen, Denmark | •••••••••••@biosyntia.com | |
Platform addressing patients' unmet medical and care needs. |
$4M | Inveready | 1 to 10 | Health Tech, Pharma | B2B | Madrid, Spain | •••••••••••@devonlabs.com | |
Biotechnology platform accelerating cancer cell therapy discoveries with AI-driven TCR-antigen screening. |
$104k · Pre Seed | Atomico, Entrepreneur First | 1 to 10 | Health Tech, AI, Biotech, Deep Tech, Pharma, Data and Analytics | B2B | London, UK | •••••••••••@exogene.co.uk | |
Glycanengineering platform. |
$49M · Series A | Sofinnova Partners | 11 to 50 | Health Tech, Biotech, Pharma | B2B | Zürich, Switzerland | •••••••••••@glycoera.com | |
AI-powered data collecting tool for clinical trials. |
$1M · Seed | Kima Ventures, Cathay Innovation, Serena | 11 to 50 | Health Tech, AI, Biotech, Machine Learning, Pharma | B2B, SaaS | Paris, France | •••••••••••@inato.com | |
Pharmaceutical developer specializing in new treatments for chronic inflammatory diseases. |
$20M · Series B | Claris Ventures, Tech4Planet | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing | B2B | Turin, Italy | •••••••••••@kitherbiotech.com | |
Synthetic biology company producing superior cannabinoids for the pharmaceutical industry. |
$4M · Series A | The Footprint Firm, Unconventional Ventures, Oskare Capital | 1 to 10 | Health Tech, Biotech, Pharma, Manufacturing | B2B | Copenhagen, Denmark | •••••••••••@octarinebio.com | |
Platform ensuring transparent and secure supply chains in life sciences at affordable costs. |
$12M · Series A | HV Capital, Cherry Ventures, H14 | 11 to 50 | AI, Pharma, Business Intelligence | B2B, Marketplace | Frankfurt, Germany | •••••••••••@qualifyze.com | |
Anti-cancer drugs ddevelopers activating protein phosphatase 2A (PP2A) |
$10M · Series A | Novo A/S, Novartis Venture Fund | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Helsinki, Finland | •••••••••••@rappta-therapeutics.com | |
Digital health platform providing instant access to private medical appointments and testing. |
$125k · Pre Seed | Y Combinator | 1 to 10 | Health Tech, CPG & Consumer Goods, Pharma | B2B, SaaS | London, UK | •••••••••••@tuli.health | |
Platform that connects patients and pharmaceutical companies to improve health outcomes. |
$2M · Seed | Aescuvest | 11 to 50 | Health Tech, Pharma, Sales and Marketing | B2B, Marketplace | Munich, Germany | •••••••••••@xo-life.com | |
Digital pharmacy platform. |
$180k · Seed | Scottish Investment Bank, Par Equity | 51 to 100 | Pharma | B2C, SaaS | London, UK | •••••••••••@wearephlo.com | |
Developer of innovative treatment for muscle wasting disorders. |
$1M · Seed | Mankind Pharma | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@actimedtherapeutics.com | ||
Testing and certifications platform for any material, product or chemical. |
$2M · Seed | VentureFriends, Lifeline Ventures | 11 to 50 | Biotech, Pharma | Helsinki, Finland | •••••••••••@measurlabs.com | ||
Therapeutic platform focused on developing treatments that promote immune tolerance. |
$29M · Series A | Caixa Capital Risc, Sound Bioventures | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Nantes, France | •••••••••••@aboleris-pharma.com | |
Platform for discovering and developing medicines to treat and prevent heart disease. |
$76M | BioMedPartners, High-Tech Gründerfonds, Inkef Capital | 11 to 50 | Health Tech, Biotech, Pharma | B2B | Hanover, Germany | •••••••••••@cardior.de | |
Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need. |
$99M | High-Tech Gründerfonds, Hadean Ventures | 1 to 10 | Health Tech, Biotech, Pharma, Fitness, Manufacturing | B2B | Duisburg, Germany | •••••••••••@emergencetx.com | |
Platform discovering and developing new drugs to treat severe fungal diseases. |
$70M | Sofinnova Partners, Novo A/S, Forbion Capital Partners | 251 to 500 | Health Tech, Biotech, Pharma, Genetics | B2B | Manchester, UK | •••••••••••@f2g.com | |
Platform for discovering new drugs for rare diseases using AI technology. |
$56M · Series B | Balderton Capital, Atomico, btov Partners | 51 to 100 | Health Tech, AI, Biotech, Pharma, Data and Analytics, Business Intelligence | B2B, SaaS | Cambridge, UK | •••••••••••@healx.io | |
Platform developing new treatments that focus on the butyrophilin family's checkpoint molecules. |
$102M | Earlybird Venture Capital, Eurazeo, Andera Partners | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Marseille, France | •••••••••••@imchecktherapeutics.com | |
Clinical-stage central nervous system (CNS) technology. |
$110M · Series B | Sofinnova Partners, Forbion Capital Partners, BioMedPartners | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Basel, Switzerland | •••••••••••@noemapharma.com | |
Lab-quality diagnostics for anyone, anywhere, at any time. |
$85M | Oxford Science Enterprises | 51 to 100 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Oxford, UK | •••••••••••@oslerdiagnostics.com | |
Platform for analyzing single molecules like DNA, RNA, and proteins using nanopore-based electronic systems. |
$275M | Wellington Management | 251 to 500 | Health Tech, Biotech, Pharma, Robotics, Manufacturing, Genetics | B2B | Oxford, UK | •••••••••••@nanoporetech.com | |
AI-powered CBT therapeutic platform. |
$130k · Pre Seed | Scale Capital, Hadean Ventures, Sweet Studio | 1 to 10 | Health Tech, AI, Pharma, Ecommerce | B2B, Marketplace | Stockholm, Sweden | •••••••••••@alextherapeutics.com | |
Platform for clinical validation and product surveillance of medical devices and pharmaceutical products. |
$1M · Pre Seed | Nauta Capital | 51 to 100 | Health Tech, Biotech, Pharma, Data and Analytics, Business Intelligence | B2B, SaaS | Munich, Germany | •••••••••••@climedo.de | |
Casein protein manufacturer for animal-free cheese. |
$5M · Seed | Climentum Capital, PUSH Ventures, BackBone Ventures | 1 to 10 | Foodtech, Biotech, Pharma, Manufacturing | B2B | Vienna, Austria | •••••••••••@fermify.org | |
Pre-clinical platform for all kinds of cancer treatment. |
$3M | Investinor | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Oslo, Norway | •••••••••••@hemispherian.com | |
Softener that improves bone cements to match the mechanical properties of osteoporotic bone. |
$330k · Pre Seed | Almi Invest | 1 to 10 | Health Tech, Hardware, Pharma | B2B | Stockholm, Sweden | •••••••••••@inossia.com | |
Biotechnology company focused on developing therapeutic medicines by harnessing gene activation mechanisms. |
$29M | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Genetics | B2B | London, UK | •••••••••••@minatx.com |
Sign up to access our full database
Enter your email and get access to 18,000+ technology companies you can partner with – 277 in Pharma.
- Manufacturing... (2541)
- Health Tech... (2480)
- Fintech... (2445)
- Ecommerce... (1779)
- AI... (1630)
- Mobile... (1588)
- Data and Analytics... (1511)
- Business Intell...... (1461)
- Hardware... (1219)
- Climate Tech & ...... (1100)
- Energy & Nuclear... (1010)
- Biotech... (993)
- Mobility & Tran...... (948)
- Sales and Marke...... (947)
- Foodtech... (927)
- Proptech & Real...... (913)
- Deep Tech... (810)
- Media and Enter...... (787)
- Crypto & web3... (703)
- Edtech... (660)
- CPG & Consumer ...... (619)
- Developer Tools... (518)
- Privacy and Sec...... (515)
- Gaming... (497)
- Payments... (496)
- Machine Learning... (475)
- Hiring and Recr...... (473)
- Communications... (469)
- Fashion... (433)
- Community & Lif...... (405)
- Travel Tech... (392)
- Agritech... (389)
- Adtech... (374)
- Legal Tech... (358)
- Sportstech... (357)
- Cybersecurity... (295)
- Consumer Social... (293)
- Supply Chain & ...... (281)
- Video... (280)
- Pharma... (278)
- Robotics... (277)
- Productivity Tools... (257)
- Creative Tools... (256)
- Enterprise Soft...... (255)
- Insuretech... (231)
- CRM... (217)
- AR / VR... (214)
- Internet of Things... (213)
- Future of Work... (210)
- Music and Audio... (199)
- Fitness... (191)
- Cloud... (190)
- Service Industry... (162)
- Investing... (138)
- Food Delivery... (138)
- Space Tech... (137)
- Wearables... (111)
- Identity Manage...... (92)
- Navigation and ...... (84)
- Electric Vehicles... (81)
- Publishing... (77)
- ElderTech... (73)
- Govtech... (71)
- Semiconductor... (69)
- Personal Finance... (67)
- Art... (66)
- Drones... (66)
- Messaging... (63)
- Open Source... (57)
- IT Management... (53)
- Pet Tech... (51)
- Quantum Computing... (50)
- FamilyTech & Pa...... (44)
- Esports... (34)
- Genetics... (28)